ArcticDx Licenses Colorectal Cancer Biomarker IP from UK's CRT

Jul 31, 2008

NEW YORK (GenomeWeb News) – Cancer Research Technology, the technology commercialization arm of Cancer Research UK, said today that it will license certain intellectual property related to colorectal cancer risk assessment to the molecular diagnostics company ArcticDx.

Under the non-exclusive license agreement, ArcticDx will pay CRT an upfront payment and royalties from any sales of the biomarker-based test it plans to develop using the technology.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

NIH Boost Proposed

A draft bill released by the US House of Representatives appropriations committee would increase the 2019 National Institutes of Health budget by 3 percent.

Police, Genealogy, and Privacy

Bloomberg looks into privacy issues raised by law enforcement's use of genetic genealogy sites.

Gotta Sequence 'Em All

NBC News reports on the Earth BioGenome Project, which aims to sequence all eukaryotic life on Earth.

This Week in Science

In Science this week: environmental DNA can help in studies of marine animals, and more.

Main menu